PET/CT Imaging for Bile Duct Cancer

This trial investigates a new method to predict treatment effectiveness for individuals with newly diagnosed bile duct cancer, also known as cholangiocarcinoma. The study employs a special imaging technique called PET/CT, combined with a radioactive tracer called [18F]FTT, to determine if it can identify cancer cells that may not respond well to the standard treatment of gemcitabine, cisplatin, and durvalumab (GCD). Success in this approach could enable doctors to tailor treatments based on the visibility of these cells in the images. Individuals with newly diagnosed bile duct cancer who plan to start GCD treatment and have at least one measurable tumor may be suitable candidates for this trial. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

In previous studies, [18F]FTT has been used in PET scans to locate cancer cells. Research shows it can detect a protein called PARP1 in cancers such as ovarian and breast cancer, aiding doctors in identifying cancer cells.

Safety information on [18F]FTT indicates it is generally well-tolerated. The procedure uses small amounts of radioactivity, similar to other PET scan tracers, and is usually safe with few side effects. Patients in earlier studies did not report any major safety issues. While minor side effects might occur, these are not well-documented in the available studies.

Researchers are excited about [18F]FTT PET/CT imaging for bile duct cancer because it offers a new way to visualize the cancer with potentially greater precision. Unlike standard imaging techniques, [18F]FTT targets specific cancer cells, allowing for clearer and more accurate images. This could lead to better treatment planning and monitoring, which is crucial for a cancer as challenging to treat as bile duct cancer. By improving the accuracy of imaging, this technique may help doctors tailor treatments more effectively, potentially improving outcomes for patients.

Research has shown that PET/CT scans using \[18F\]FTT can detect specific cancer markers in cholangiocarcinoma, a type of bile duct cancer. In this trial, participants will receive \[18F\]FTT as part of the diagnostic PET/CT imaging. \[18F\]FTT targets PARP1, a protein sometimes present in these tumors. Studies have found that identifying PARP1 can help pinpoint tumors that might not respond well to common treatments like gemcitabine, cisplatin, and durvalumab. PET/CT accurately identifies individuals without the disease, making it a valuable tool for distinguishing certain tumor cell types. This imaging method could help doctors better predict and understand patient responses to treatment.⁶⁷⁸⁹¹⁰